ICICI Securities has started coverage on Fortis Healthcare with a 'BUY' rating and a price target of Rs 1,075. The brokerage highlights the company's planned hospital bed expansion and revenue growth, noting that these positives may help offset short-term pressure on profit margins.
ICICI Securities has initiated coverage on Fortis Healthcare with a 'BUY' rating, setting a price target of Rs 1,075. The brokerage's positive outlook follows the company's performance in the first quarter of fiscal year 2027, where it reported consolidated revenue of Rs 2,545 crore, representing a 17.5% year-on-year increase. The company's operating EBITDA for the same period stood at Rs 568 crore.
Expansion and Investment Strategy
Fortis Healthcare is focusing on increasing its capacity to capture demand. The company has laid out plans to add between 400 and 500 beds during the current fiscal year. A significant part of this growth strategy includes a new Rs 252 crore investment dedicated to a Proton therapy facility in Gurugram. This move is part of a broader effort to strengthen its specialized medical services.
While the company is growing its infrastructure, there is pressure on profit margins. This has been driven by the costs associated with employee stock option plans (ESOPs) and higher overhead expenses at new facilities. Due to these factors, ICICI Securities has adjusted its EBITDA estimates for FY27 and FY28 downwards by 6% and 4%, respectively. The brokerage expects that the successful ramp-up of new bed capacities and improved occupancy at key facilities will be critical for future margin stability.
Diagnostics and Financial Health
The company’s diagnostics division is showing signs of recovery, with margins improving by 120 basis points compared to the previous year. The recent appointment of a new CEO for this segment is seen as a strategic step to drive growth and operational efficiency.
On the balance sheet, Fortis Healthcare reported a net debt of Rs 2,233 crore as of June 30, 2026. This translates to a net debt-to-EBITDA ratio of 1.01x, which indicates a manageable level of debt relative to operating earnings. Investors, however, should keep track of ongoing legal and arbitration proceedings, including the long-standing case involving Daiichi Sankyo, which remains a key monitorable. Additionally, market participants may note that Fortis Healthcare is scheduled to be excluded from the Nifty Midcap 150 index in a periodic review effective September 30, 2026.
The next important updates for investors will be the progress on the Proton therapy facility construction and the pace at which the new hospital beds are commissioned and filled with patients, as these will directly influence future revenue and margin trends.